GlassScriptPhysician profile
Cindy M Molina
NPI 1487209250
$5,229.63
in general payments reported to CMS, 2019-2025
28 companies · $775 in 2025
The $775 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $966 · 2022: $813 · 2023: $1,188 · 2024: $1,488 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,450.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $917.68 | 2021-2025 | |
| Novo Nordisk INC | $633.71 | 2021-2023 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $483.92 | 2021-2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.08 | 2021-2024 | Jardiance, Ofev |
| Optinose US, INC. | $308.97 | 2024-2025 | |
| Glaxosmithkline, LLC. | $282.88 | 2022-2025 | Arexvy, Nucala |
| Biohaven Pharmaceuticals, INC. | $282.18 | 2021 | |
| Lilly USA, LLC | $259.81 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $253.96 | 2023-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $184.23 | 2024-2025 | Fasenra, Airsupra |
| Otsuka America Pharmaceutical, INC. | $144.05 | 2021-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $136.57 | 2024-2025 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $121.32 | 2024 | Uptravi, Opsumit |
| Janssen Biotech, INC. | $117.99 | 2024 | Simponi Aria, Tremfya |
| Sumitomo Pharma America, INC. | $93.61 | 2023 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $86.93 | 2025 | Tula |
| Mylan Specialty L.P. | $80.17 | 2023-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $71.46 | 2024-2025 | Dupixent |
| Baxter Healthcare | $64.20 | 2023 | Hillrom - Life 2000 Ventilation System |
| Ani Pharmaceuticals, INC. | $53.75 | 2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $39.50 | 2021 | |
| Dexcom, INC. | $27.87 | 2024 | Dexcom G6 Transmitter |
| Globus Medical, INC. | $24.22 | 2022 | |
| Genentech USA, INC. | $23.68 | 2024 | Actemra |
| Organon LLC | $22.43 | 2024 | |
| Emd Serono, INC. | $21.49 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.17 | 2024 | Orencia |
| Vertex Pharmaceuticals Incorporated | $18.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Molina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.